文献速递心力衰竭与心肌病瓣膜病与结构性心脏病

Patisiran(RNA干扰疗法)对遗传性转甲状腺素蛋白淀粉样变性患者心脏参数的影响

Effects of Patisiran, an RNA Interference Therapeutic, on Cardiac Parameters in Patients With Hereditary Transthyretin-Mediated Amyloidosis.
PubMed 文献 · Circulation · 2019-01-01

APOLLO 3期随机双盲安慰剂对照试验纳入遗传性转甲状腺素蛋白淀粉样变性(hATTR)患者,预设心脏亚组(n=126)基线左室壁厚度≥13 mm且无高血压或主动脉瓣病史。18个月时Patisiran较安慰剂降低平均左室壁厚度、整体纵向应变和NT-proBNP,并改善部分心脏结构功能参数,事后分析显示心脏住院和全因死亡复合终点风险有降低趋势。

要点

  • Patisiran降低心脏亚组平均左室壁厚度(差异-0.9±0.4 mm,P=0.017)。
  • Patisiran降低整体纵向应变(-1.4±0.6%,P=0.015)和NT-proBNP(18个月比值0.45,P<0.001)。
  • 事后分析心脏住院和全因死亡复合终点风险比0.54(95%CI 0.28-1.01)。

核心结论

  • Patisiran在18个月时较安慰剂降低平均左室壁厚度、整体纵向应变、NT-proBNP及不良心脏结局,提示可能延缓或逆转hATTR淀粉样变性心脏表现。

研究设计与样本

  • APOLLO为国际多中心、随机、双盲、安慰剂对照3期试验,hATTR淀粉样变性患者按2:1随机接受0.3 mg/kg Patisiran或安慰剂静脉输注每3周一次共18个月。
  • 预设心脏亚组纳入基线左室壁厚度≥13 mm且无高血压或主动脉瓣病史者(n=126,占总体56%),中位随访18.7个月。
  • 总体APOLLO人群(n=225)也评估了心脏参数,心脏住院和全因死亡复合终点为事后分析。

主要发现

  • 心脏亚组18个月时Patisiran较安慰剂降低平均左室壁厚度(最小二乘均值差异±SEM:-0.9±0.4 mm,P=0.017)、室间隔壁厚度、后壁厚度和相对壁厚度。
  • 心脏亚组18个月时Patisiran较安慰剂增加舒张末期容积(8.3±3.9 mL,P=0.036)、降低整体纵向应变(-1.4±0.6%,P=0.015)、增加心输出量(0.38±0.19 L/min,P=0.044)。
  • Patisiran在9和18个月降低NT-proBNP(18个月Patisiran/安慰剂倍数变化比值0.45,P<0.001),总体APOLLO人群18个月NT-proBNP效果一致。
  • 事后分析心脏住院和全因死亡暴露调整率分别为安慰剂组18.7/100患者年、Patisiran组10.1/100患者年(Andersen-Gill风险比0.54;95%CI 0.28-1.01)。

关键数值与推荐

  • 预设心脏亚组标准:基线左室壁厚度≥13 mm且无高血压或主动脉瓣疾病史。
  • Patisiran剂量0.3 mg/kg静脉输注每3周一次,共18个月。

临床怎么用

  • 对于hATTR淀粉样变性伴心脏受累(左室壁厚度≥13 mm且无高血压或主动脉瓣病)的患者,Patisiran可能改善心脏结构和功能参数并降低NT-proBNP。
  • 心脏住院和全因死亡复合终点的风险降低趋势需结合事后分析性质谨慎解读。

局限性

  • 心脏住院和全因死亡复合终点为事后分析,风险比95%CI上限跨越1.01。
  • 心脏亚组为预设亚组,样本量有限(n=126)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Hereditary transthyretin-mediated (hATTR) amyloidosis is a rapidly progressive, multisystem disease that presents with cardiomyopathy or polyneuropathy. The APOLLO study assessed the efficacy and tolerability of patisiran in patients with hATTR amyloidosis. The effects of patisiran on cardiac structure and function in a prespecified subpopulation of patients with evidence of cardiac amyloid involvement at baseline were assessed. METHODS: APOLLO was an international, randomized, double-blind, placebo-controlled phase 3 trial in patients with hATTR amyloidosis. Patients were randomized 2:1 to receive 0.3 mg/kg patisiran or placebo via intravenous infusion once every 3 weeks for 18 months. The prespecified cardiac subpopulation comprised patients with a baseline left ventricular wall thickness ≥13 mm and no history of hypertension or aortic valve disease. Prespecified exploratory cardiac end points included mean left ventricular wall thickness, global longitudinal strain, and N-terminal prohormone of brain natriuretic peptide. Cardiac parameters in the overall APOLLO patient population were also evaluated. A composite end point of cardiac hospitalizations and all-cause mortality was assessed in a post hoc analysis. RESULTS: In the cardiac subpopulation (n=126; 56% of total population), patisiran reduced mean left ventricular wall thickness (least-squares mean difference ± SEM: -0.9±0.4 mm, P=0.017), interventricular septal wall thickness, posterior wall thickness, and relative wall thickness at month 18 compared with placebo. Patisiran also led to increased end-diastolic volume (8.3±3.9 mL, P=0.036), decreased global longitudinal strain (-1.4±0.6%, P=0.015), and increased cardiac output (0.38±0.19 L/min, P=0.044) compared with placebo at month 18. Patisiran lowered N-terminal prohormone of brain natriuretic peptide at 9 and 18 months (at 18 months, ratio of fold-change patisiran/placebo 0.45, P<0.001). A consistent effect on N-terminal prohormone of brain natriuretic peptide at 18 months was observed in the overall APOLLO patient population (n=225). Median follow-up duration was 18.7 months. The exposure-adjusted rates of cardiac hospitalizations and all-cause death were 18.7 and 10.1 per 100 patient-years in the placebo and patisiran groups, respectively (Andersen-Gill hazard ratio, 0.54; 95% CI, 0.28-1.01). CONCLUSIONS: Patisiran decreased mean left ventricular wall thickness, global longitudinal strain, N-terminal prohormone of brain natriuretic peptide, and adverse cardiac outcomes compared with placebo at month 18, suggesting that patisiran may halt or reverse the progression of the cardiac manifestations of hATTR amyloidosis. CLINICAL TRIAL REGISTRATION: URL: https://www.clinicaltrials.gov . Unique identifier: NCT01960348.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Solomon SD, Adams D, Kristen A, et al. Effects of Patisiran, an RNA Interference Therapeutic, on Cardiac Parameters in Patients With Hereditary Transthyretin-Mediated Amyloidosis. Circulation. 2019. PMID: 30586695. doi:10.1161/CIRCULATIONAHA.118.035831

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。